Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells

Journal of Autoimmunity

Volumn 35, Issue 3, 2010, Pages 269-275

  Scheinecker, Clemens ^a   Bonelli, Michael ^a   Smolen, Josef S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Autoimmunity; Foxp3; Regulatory T cells; Systemic lupus erythematodes

Indexed keywords

ABATACEPT; CYCLOPHOSPHAMIDE; CYTOKINE; GLUCOCORTICOID; LYMPHOCYTE SURFACE MARKER; RITUXIMAB; TUMOR NECROSIS FACTOR;

ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; DRUG TARGETING; GENETIC HETEROGENEITY; HUMAN; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 77957801548     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2010.06.018     Document Type: Article

References (58)

1. Deicher H.R., Holman H.R., Kunkel H.G. The precipitin reaction between DNA and a serum factor in systemic lupus erythematosus. J Exp Med 1959, 109:97-114.
2. Morel L., Croker B.P., Blenman K.R., Mohan C., Huang G., Gilkeson G., et al. Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc Natl Acad Sci U S A 2000, 97:6670-6675.
3. Favas C., Isenberg D.A. B-cell-depletion therapy in SLE - what are the current prospects for its acceptance?. Nat Rev Rheumatol 2009, 5:711-716.
4. Ivashkiv L.B. Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis. Autoimmunity 2003, 36:473-479.
5. Hooks J.J., Jordan G.W., Cupps T., Moutsopoulos H.M., Fauci A.S., Notkins A.L. Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum 1982, 25:396-400.
6. Moutsopoulos H.M., Hooks J.J. Interferon and autoimmunity. Clin Exp Rheumatol 1983, 1:81-84.
7. Marshak-Rothstein A., Rifkin I.R. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 2007, 25:419-441.
8. Karonitsch T., Feierl E., Steiner C.W., Dalwigk K., Korb A., Binder N., et al. Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum 2009, 60:1463-1471.
9. Aringer M., Smolen J.S. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 2008, 10:202.
10. Gottlieb A.B., Lahita R.G., Chiorazzi N., Kunkel H.G. Immune function in systemic lupus erythematosus. Impairment of in vitro T-cell proliferation and in vivo antibody response to exogenous antigen. J Clin Invest 1979, 63:885-892.
11. Sakane T., Steinberg A.D., Green I. Failure of autologous mixed lymphocyte reactions between T and non-T cells in patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A 1978, 75:3464-3468.
12. Koller M.D., Kiener H.P., Aringer M., Graninger W.B., Meuer S., Samstag Y., et al. Functional and molecular aspects of transient T cell unresponsiveness: role of selective interleukin-2 deficiency. Clin Exp Immunol 2003, 132:225-231.
13. Scheinecker C., Zwolfer B., Koller M., Manner G., Smolen J.S. Alterations of dendritic cells in systemic lupus erythematosus: phenotypic and functional deficiencies. Arthritis Rheum 2001, 44:856-865.
14. Koller M., Zwolfer B., Steiner G., Smolen J.S., Scheinecker C. Phenotypic and functional deficiencies of monocyte-derived dendritic cells in systemic lupus erythematosus (SLE) patients. Int Immunol 2004, 16:1595-1604.
15. Basten A., Fazekas de St Groth B. Special regulatory T-cell review: T-cell dependent suppression revisited. Immunology 2008, 123:33-39.
16. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
17. Suri-Payer E., Amar A.Z., Thornton A.M., Shevach E.M. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998, 160:1212-1218.
18. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
19. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001, 167:1245-1253.
20. Corthay A. How do regulatory T cells work?. Scand J Immunol 2009, 70:326-336.
21. Josefowicz S.Z., Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 2009, 30:616-625.
22. Roncarolo M.G., Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells?. Eur J Immunol 2008, 38:925-927.
23. Brusko T.M., Putnam A.L., Bluestone J.A. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 2008, 223:371-390.
24. Bonelli M., von Dalwigk K., Savitskaya A., Smolen J.S., Scheinecker C. Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis. Ann Rheum Dis 2008, 67:664-671.
25. Studnicka-Benke A., Steiner G., Petera P., Smolen J.S. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996, 35:1067-1074.
26. Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299:1033-1036.
27. Xu L., Kitani A., Fuss I., Strober W. Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol 2007, 178:6725-6729.
28. Ouyang W., Kolls J.K., Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467.
29. Wong C.K., Lit L.C., Tam L.S., Li E.K., Wong P.T., Lam C.W. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008, 127:385-393.
30. Aringer M., Stummvoll G.H., Steiner G., Koller M., Steiner C.W., Hofler E., et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford) 2001, 40:876-881.
31. Valencia X., Stephens G., Goldbach-Mansky R., Wilson M., Shevach E.M., Lipsky P.E. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006, 108:253-261.
32. Bonelli M., Savitskaya A., Steiner C.W., Rath E., Smolen J.S., Scheinecker C. Phenotypic and functional analysis of CD4+CD25-Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunol 2009, 182:1689-1695.
33. Yang H.X., Zhang W., Zhao L.D., Li Y., Zhang F.C., Tang F.L., et al. Are CD4+CD25-Foxp3+ cells in untreated new-onset lupus patients regulatory T cells?. Arthritis Res Ther 2009, 11:R153.
34. Tran D.Q., Andersson J., Hardwick D., Bebris L., Illei G.G., Shevach E.M. Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood 2009, 113:5125-5133.
35. Tran D.Q., Andersson J., Wang R., Ramsey H., Unutmaz D., Shevach E.M. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A 2009, 106:13445-13450.
36. Rebollo A., Schmitt C. Ikaros, Aiolos and Helios: transcription regulators and lymphoid malignancies. Immunol Cell Biol 2003, 81:171-175.
37. Thornton A.M., Korty P.E., Tran D.Q., Wohlfert E.A., Murray P.E., Belkaid Y., et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010.
38. Thornton A.M., Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188:287-296.
39. Takahashi T., Kuniyasu Y., Toda M., Sakaguchi N., Itoh M., Iwata M., et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998, 10:1969-1980.
40. Walker L.S., Chodos A., Eggena M., Dooms H., Abbas A.K. Antigen-dependent proliferation of CD4+CD25+ regulatory T cells in vivo. J Exp Med 2003, 198:249-258.
41. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007, 7:875-888.
42. Miyara M., Amoura Z., Parizot C., Badoual C., Dorgham K., Trad S., et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005, 175:8392-8400.
43. Franz B., Fritzsching B., Riehl A., Oberle N., Klemke C.D., Sykora J., et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum 2007, 56:1910-1920.
44. Looney R.J., Anolik J., Sanz I. A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol 2009, 20:1-10.
45. Furie R., Stohl W., Ginzler E.M., Becker M., Mishra N., Chatham W., et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008, 10:R109.
46. Dall'era M., Wofsy D. Connective tissue diseases: belimumab for systemic lupus erythematosus: breaking through?. Nat Rev Rheumatol 2010, 6:124-125.
47. Aringer M., Smolen J.S., Graninger W.B. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheum 1998, 41:414-420.
48. Stummvoll G.H., Aringer M., Smolen J.S., Schmaldienst S., Jimenez-Boj E., Horl W.H., et al. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 2005, 64:1015-1021.
49. Daikh D.I., Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001, 166:2913-2916.
50. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, et al. Activity of abatacept in SLE: results of a 12-month phase II exploratory study. In: Annual European Congress of Rheumatology (EULAR). Stockholm, Sweden. 2009.
51. Illei G.G., Shirota Y., Yarboro C.H., Daruwalla J., Tackey E., Takada K., et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010, 62:542-552.
52. Aringer M., Graninger W.B., Steiner G., Smolen J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004, 50:3161-3169.
53. Horwitz D.A. Regulatory T cells in systemic lupus erythematosus: past, present and future. Arthritis Res Ther 2008, 10:227.
54. Walker L.S., Abbas A.K. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol 2002, 2:11-19.
55. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
56. Ansari A.A., Gershwin M.E. Navigating the passage between Charybdis and Scylla: recognizing the achievements of Noel Rose. J Autoimmun 2009, 33:165-169.
57. Whittingham S., Rowley M.J., Gershwin M.E. A tribute to an outstanding immunologist - Ian Reay Mackay. J Autoimmun 2008, 31:197-200.
58. Gershwin M.E. Bone marrow transplantation, refractory autoimmunity and the contributions of Susumu Ikehara. J Autoimmun 2008, 30:105-107.